Mizuho Securities Raises Price Target on Sucampo Pharma (SCMP) Following 3Q Beat and Raise
Get Alerts SCMP Hot Sheet
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 7
Join SI Premium – FREE
Mizuho Securities reiterated a Neutral rating on Sucampo Pharmaceuticals (NASDAQ: SCMP), and raised the price target to $16.00 (from $13.00), following the company's 3Q earnings report. SCMP reported 3Q:16 revenue of $57.9M and $0.28 in EPS vs. consensus of $51.3M and $0.27. Management raised its 2016 revenue guidance to $220-$225M (from $195-$205M) and EPS of $1.20-$1.25 (from $0.97-$1.07).
Analyst Irina Koffler "We realize we missed the big move in the stock after a strong 3Q:16. However we see little momentum from here. We reiterate our Neutral rating and raise PT to $16 from $13."
For an analyst ratings summary and ratings history on Sucampo Pharmaceuticals click here. For more ratings news on Sucampo Pharmaceuticals click here.
Shares of Sucampo Pharmaceuticals closed at $15.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intermediate Capital Group (ICP:LN) (ICGUF) PT Raised to GBP22.50 at Citi
- Lam Research (LRCX) PT Raised to $1,130 at B.Riley
- Synchrony Financial (SYF) PT Raised to $41 at BMO Capital
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Earnings, Irina KofflerSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!